FDA puts hold on Gilead's blood cancer therapy trials

Gilead Sciences (GILD.O), opens new tab said on Wednesday the U.S. Food and Drug Administration had put a hold on trials testing the company's blood cancer drug following increased risk of patient death in some studies.